Lipid nanoparticles loaded with 10-hydroxycamptothecinphospholipid complex developed for the treatment of hepatoma in clinical application

Journal of Drug Targeting

Volumn 18, Issue 7, 2010, Pages 557-566

  Wei, Wei ^a   Shi, San Jun ^a   Liu, Jie ^a   Sun, Xun ^a   Ren, Ke ^a   Zhao, Dong ^a   Zhang, Xiao Ning ^b   Zhang, Zhi Rong ^a   Gong, Tao ^a  

^a SICHUAN UNIVERSITY   (China)

^b Tsinghua University   (China)

Author keywords

10 Hydroxycamptothecin; Cellular uptake; Clinical application; Hepatoma uptake; Lipid nanoparticles; Phospholipid complex

Indexed keywords

10 HYDROXYCAMPTOTHECIN; PHOSPHOLIPID; SOLID LIPID NANOPARTICLE; 10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DELAYED RELEASE FORMULATION; DRUG CARRIER; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; DRUG TUMOR LEVEL; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; FEMALE; HEPG2 CELL LINE; HUMAN; LIVER NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; PARTICLE SIZE; PHOSPHOLIPIDS; TISSUE DISTRIBUTION;

EID: 77954295368     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003599461     Document Type: Article

References (26)

1. Chiannilkulchai N, Ammoury N, Caillou B, Devissaguet JP, Couvreur P. (1990). Hepatic tissue distribution of doxorubicin-loaded nan-oparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother Pharmacol, 26, 122-126.
2. Joshi MD, Müller RH. (2009). Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm, 71, 161-172.
3. Kathryn CP, Gregory ML, Samuel AW. (2008). Exploiting lipid raft transport with membrane targeted nanoparticles: A strategy for cytosolic drug delivery. Biomaterials, 29, 3367-3375.
4. Li Q, Wang Y, Feng N, Fan Z, Sun J, Nan Y. (2008). Novel polymeric nanoparticles containing tanshinone IIA for the treatment of hepatoma. J Drug Target, 16, 725-732.
5. Maiti K, Mukherjee K, Gantait A, Ahamed HN, Saha BP, Mukherjee PK. (2005). Enhanced therapeutic beneft of quercetin-phospholipid complex in carbon tetrachloride induced acute liver injury in rats: a comparative study. Iran J Pharmacol Ter, 4, 84-90.
6. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. (2007). Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm, 330, 155-163.
7. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63.
8. O'Leary J, Muggia FM. (1998). Camptothecins: a review of their development and schedules of administration. Eur J Cancer, 34, 1500-1508.
9. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, Okano T. (2004). Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm Res, 21, 2001-2008.
10. Rivory LP, Robert J. (1995). Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol Ter, 68, 269-296.
11. Shao K, Hou Q, Duan W, Go ML, Wong KP, Li QT. (2006). Intracellular drug delivery by sulfatide-mediated liposomes to gliomas. J Control Release, 115, 150-157.
12. Soma CE, Dubernet C, Barratt G, Benita S, Couvreur P. (2000). Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J Control Release, 68, 283-289.
13. Stoye I, Schröder K, Müller-Goymann CC. (1998). Transformation of a liposomal dispersion containing ibuprofen lysinate and phos-pholipids into mixed micelles\physico-chemical characterization and infuence on drug permeation through excised human stratum corneum. Eur J Pharm Biopharm, 46, 191-200.
14. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. (1966). Plant antitumor agents. I. Te isolation and structure of camp-tothecin, a novel alkaloidal leukemia and tumour inhibitor from camptotheca acuminata. J Am Chem Soc, 88, 3888-3890.
15. Wei W, Zhao D, Zhang ZR, Gong T. (2008). Study on the physico-chemical properties of hydroxycamptothecin-phospholipid complex. West China J Pharm Sci, 23, 396-399.
16. Wu Y, He W, Dai WB, Zhou BH, Song JC. (2005). Study on formulation and preparation of chitosan chloride coated hydroxycamp-tothecin nanoliposomes. Chin Pharm J, 40, 922-925.
17. Xiao YY, Song YM, Chen ZP, Ping QN. (2006). Te preparation of silybin-phospholipid complex and the study on its pharmacoki-netics in rats. Int J Pharm, 307, 77-82.
18. Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q. (2005). Enhanced intracellular delivery and improved antitu-mor efcacy of doxorubicin by sterically stabilized liposomes modifed with a synthetic RGD mimetic. J Control Release, 107, 262-275.
19. Yang L, Cui F, Cun D, Tao A, Shi K, Lin W. (2007). Preparation, characterization and biodistribution of the lactone form of 10- hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int J Pharm, 340, 163-172.
20. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting efect on brain. J Control Release, 59, 299-307.
21. Zhang C, Ding Y, Yu LL, Ping Q. (2007). Polymeric micelle systems of hydroxycamptothecin based on amphiphilic N-alkyl-N-trimethyl chitosan derivatives. Colloids Surf B Biointerfaces, 55, 192-199.
22. Zhang L, Hu Y, Jiang X, Yang C, Lu W, Yang YH. (2004). Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co- lactide) nanoparticles and their biodis-tribution in mice. J Control Release, 96, 135-148.
23. Zhang L, Yang M, Wang Q, Li Y, Guo R, Jiang X, Yang C, Liu B. (2007). 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Control Release, 119, 153-162.
24. Zhang XX, Gan Y, Yang XG, Zhu CL, Gan L, Nie SF, Pan WS. (2008). [Preparation of PEG-modifed nanostructured lipid carriers loaded with hydroxycamptothecin and tissue distribution in mice]. Yao Xue Xue Bao, 43, 91-96.
25. Zhao D, Gong T, Fu Y, Nie Y, He LL, Liu J, Zhang ZR. (2008). Lyophilized Cheliensisin A submicron emulsion for intravenous injection: characterization, in vitro and in vivo antitumor efect. Int J Pharm, 357, 139-147.
26. Zhao YZ, Luo YK, Liang HD, Mei XG, Tang J, Lu CT, Zhang Y, Lin Q. (2006). Comparing transfection efciency and safety for anti-sense oligodeoxyribonucleotide between phospholipids-based microbubbles and liposomes. J Drug Target, 14, 687-693.